| Year |
Citation |
Score |
| 2018 |
Wang G, Xiong C, McDade EM, Hassenstab J, Aschenbrenner AJ, Fagan AM, Benzinger TLS, Gordon BA, Morris JC, Li Y, Bateman RJ. Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 4: 669-676. PMID 30569014 DOI: 10.1016/J.Trci.2018.10.009 |
0.31 |
|
| 2018 |
Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, et al. CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. Embo Molecular Medicine. PMID 30482868 DOI: 10.15252/Emmm.201809712 |
0.331 |
|
| 2018 |
Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, Møller I, Grøntvedt GR, Bråthen G, Patra K, Bu G, Benzinger TLS, Karch CM, Fagan A, Morris JC, Bateman RJ, et al. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease. Acta Neuropathologica Communications. 6: 130. PMID 30477568 DOI: 10.1186/S40478-018-0624-Z |
0.308 |
|
| 2018 |
Gangishetti U, Christina Howell J, Perrin RJ, Louneva N, Watts KD, Kollhoff A, Grossman M, Wolk DA, Shaw LM, Morris JC, Trojanowski JQ, Fagan AM, Arnold SE, Hu WT. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimer's Research & Therapy. 10: 98. PMID 30253800 DOI: 10.1186/S13195-018-0426-3 |
0.305 |
|
| 2016 |
Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Science Translational Medicine. 8: 338ra66. PMID 27169802 DOI: 10.1126/Scitranslmed.Aaf2362 |
0.304 |
|
| 2015 |
Ryan DJ, Kenny RA, Christensen S, Meaney JF, Fagan AJ, Harbison J. Ischaemic stroke or TIA in older subjects associated with impaired dynamic blood pressure control in the absence of severe large artery stenosis. Age and Ageing. 44: 655-61. PMID 25716898 DOI: 10.1093/Ageing/Afv011 |
0.308 |
|
| 2015 |
Wang L, Benzinger TL, Hassenstab J, Blazey T, Owen C, Liu J, Fagan AM, Morris JC, Ances BM. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease. Neurology. 84: 1254-60. PMID 25716355 DOI: 10.1212/Wnl.0000000000001401 |
0.311 |
|
| 2014 |
Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Science Translational Medicine. 6: 226ra30. PMID 24598588 DOI: 10.1126/Scitranslmed.3007901 |
0.329 |
|
| 2012 |
Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a006221. PMID 22951438 DOI: 10.1101/cshperspect.a006221 |
0.303 |
|
| 2011 |
Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Annals of Neurology. 70: 274-85. PMID 21823155 DOI: 10.1002/Ana.22448 |
0.304 |
|
| 2011 |
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 280-92. PMID 21514248 DOI: 10.1016/J.Jalz.2011.03.003 |
0.303 |
|
| 2011 |
Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, ... ... Fagan AM, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. Plos One. 6: e16032. PMID 21264269 DOI: 10.1371/Journal.Pone.0016032 |
0.308 |
|
| 2010 |
Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, ... ... Fagan AM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry. 68: 903-12. PMID 21035623 DOI: 10.1016/J.Biopsych.2010.08.025 |
0.321 |
|
| Show low-probability matches. |